Recombinant Erythropoietin for Chemotherapy-Related Anaemia

Diego Ossa (), Andrew Briggs, Emma McIntosh, Warren Cowell, Tim Littlewood and Mark Sculpher

PharmacoEconomics, 2007, vol. 25, issue 3, 223-237

Abstract: The results highlight a societal view that the severity of chemotherapy- related anaemia will significantly affect cancer patients’ HR-QOL. The DCE survey shows that the public value favourably the attributes of treatment with recombinant erythropoietin, and indicates a likely patient preference for treatment with recombinant erythropoietin over blood transfusion Copyright Adis Data Information BV 2007

Date: 2007
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200725030-00005 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:25:y:2007:i:3:p:223-237

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200725030-00005

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().